ArcticZymes EU Virus-X Consortium Awarded $9M to Mine Viral Biological Diversity Premium As part of the effort, Virus.X also aims to craft new sequencing approaches, bioinformatics tools, and targeted gene products. EU's Horizon 2020 Awards ArcticZymes €460K Grant The Biotec Pharmacon subsidiary is taking part in the Virus-X EU Consortium by developing new viral enzymes and bringing them to the market. ArcticZymes Inks Enzyme Supply Agreement with GE Healthcare Life Sciences Premium ArcticZymes said last week that it has inked a supply agreement with GE Healthcare Life Sciences for products based on ArcticZymes' portfolio of heat-labile enzymes. New England Biolabs to Distribute ArcticZymes' SAP Enzyme Premium ArcticZymes and New England Biolabs have signed a supply agreement for ArcticZymes' recombinant shrimp alkaline phosphatase, or SAP, enzyme. Norway's ArcticZymes Opens US Office; Expects Continued Growth in 2012 Premium By Ben Butkus ArcticZymes, a Norwegian life science research tools firm specializing in cold-adapted and heat-labile enzymes for use in molecular biology and diagnostics, this week opened its first US office in the outskirts of Philadelphia. Jan 12, 2012 People in the News: New Hires at ArcticZymes, IntegenX, GenturaDx, GeneThera Premium Sep 26, 2011 Biotec Pharmacon, ArcticZymes, Affymetrix Reach New Deal for Shrimp Alkaline Phosphatase Jul 14, 2011 ArcticZymes and Tataa Biocenter Strike Sales and Distribution Pact Premium Jul 13, 2011 ArcticZymes, Tataa Ink Sales, Distribution Deal Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.